Literature DB >> 23813283

Case-only method for cause-specific hazards models with application to assessing differential vaccine efficacy by viral and host genetics.

James Y Dai1, Shuying S Li, Peter B Gilbert.   

Abstract

Cause-specific proportional hazards models are commonly used for analyzing competing risks data in clinical studies. Motivated by the objective to assess differential vaccine protection against distinct pathogen types in randomized preventive vaccine efficacy trials, we present an alternative case-only method to standard maximum partial likelihood estimation that applies to a rare failure event, e.g. acquisition of HIV infection. A logistic regression model is fit to the counts of cause-specific events (infecting pathogen type) within study arms, with an offset adjusting for the randomization ratio. This formulation of cause-specific hazard ratio estimation permits immediate incorporation of host-genetic factors to be assessed as effect modifiers, an important area of vaccine research for identifying immune correlates of protection, thus inheriting the estimation efficiency, and cost benefits of the case-only estimator commonly used for assessing gene-treatment interactions. The method is used to reassess HIV genotype-specific vaccine efficacy in the RV144 trial, providing nearly identical results to standard Cox methods, and to assess if and how this vaccine efficacy depends on Fc-γ receptor genes.

Entities:  

Keywords:  Gene–treatment interaction; Sieve analysis; Vaccine efficacy

Mesh:

Year:  2013        PMID: 23813283      PMCID: PMC3862206          DOI: 10.1093/biostatistics/kxt018

Source DB:  PubMed          Journal:  Biostatistics        ISSN: 1465-4644            Impact factor:   5.899


  10 in total

1.  Simultaneously testing for marginal genetic association and gene-environment interaction.

Authors:  James Y Dai; Benjamin A Logsdon; Ying Huang; Li Hsu; Alexander P Reiner; Ross L Prentice; Charles Kooperberg
Journal:  Am J Epidemiol       Date:  2012-07-06       Impact factor: 4.897

2.  Case-only analysis of treatment-covariate interactions in clinical trials.

Authors:  E Vittinghoff; D C Bauer
Journal:  Biometrics       Date:  2006-09       Impact factor: 2.571

3.  Immune-correlates analysis of an HIV-1 vaccine efficacy trial.

Authors:  Barton F Haynes; Peter B Gilbert; M Juliana McElrath; Susan Zolla-Pazner; Georgia D Tomaras; S Munir Alam; David T Evans; David C Montefiori; Chitraporn Karnasuta; Ruengpueng Sutthent; Hua-Xin Liao; Anthony L DeVico; George K Lewis; Constance Williams; Abraham Pinter; Youyi Fong; Holly Janes; Allan DeCamp; Yunda Huang; Mangala Rao; Erik Billings; Nicos Karasavvas; Merlin L Robb; Viseth Ngauy; Mark S de Souza; Robert Paris; Guido Ferrari; Robert T Bailer; Kelly A Soderberg; Charla Andrews; Phillip W Berman; Nicole Frahm; Stephen C De Rosa; Michael D Alpert; Nicole L Yates; Xiaoying Shen; Richard A Koup; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Nelson L Michael; Jerome H Kim
Journal:  N Engl J Med       Date:  2012-04-05       Impact factor: 91.245

4.  The analysis of failure times in the presence of competing risks.

Authors:  R L Prentice; J D Kalbfleisch; A V Peterson; N Flournoy; V T Farewell; N E Breslow
Journal:  Biometrics       Date:  1978-12       Impact factor: 2.571

5.  Applying Cox regression to competing risks.

Authors:  M Lunn; D McNeil
Journal:  Biometrics       Date:  1995-06       Impact factor: 2.571

6.  Non-hierarchical logistic models and case-only designs for assessing susceptibility in population-based case-control studies.

Authors:  W W Piegorsch; C R Weinberg; J A Taylor
Journal:  Stat Med       Date:  1994-01-30       Impact factor: 2.373

7.  Comparison of competing risks failure time methods and time-independent methods for assessing strain variations in vaccine protection.

Authors:  P B Gilbert
Journal:  Stat Med       Date:  2000-11-30       Impact factor: 2.373

8.  Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand.

Authors:  Supachai Rerks-Ngarm; Punnee Pitisuttithum; Sorachai Nitayaphan; Jaranit Kaewkungwal; Joseph Chiu; Robert Paris; Nakorn Premsri; Chawetsan Namwat; Mark de Souza; Elizabeth Adams; Michael Benenson; Sanjay Gurunathan; Jim Tartaglia; John G McNeil; Donald P Francis; Donald Stablein; Deborah L Birx; Supamit Chunsuttiwat; Chirasak Khamboonruang; Prasert Thongcharoen; Merlin L Robb; Nelson L Michael; Prayura Kunasol; Jerome H Kim
Journal:  N Engl J Med       Date:  2009-10-20       Impact factor: 91.245

9.  Statistical methods for assessing differential vaccine protection against human immunodeficiency virus types.

Authors:  P B Gilbert; S G Self; M A Ashby
Journal:  Biometrics       Date:  1998-09       Impact factor: 2.571

10.  Increased HIV-1 vaccine efficacy against viruses with genetic signatures in Env V2.

Authors:  Morgane Rolland; Paul T Edlefsen; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Tomer Hertz; Allan C deCamp; Chris Carrico; Sergey Menis; Craig A Magaret; Hasan Ahmed; Michal Juraska; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; Jason S McLellan; Ivelin Georgiev; Peter D Kwong; Jonathan M Carlson; Nelson L Michael; William R Schief; Peter B Gilbert; James I Mullins; Jerome H Kim
Journal:  Nature       Date:  2012-09-10       Impact factor: 49.962

  10 in total
  8 in total

1.  Analysis of HLA A*02 association with vaccine efficacy in the RV144 HIV-1 vaccine trial.

Authors:  Andrew J Gartland; Sue Li; John McNevin; Georgia D Tomaras; Raphael Gottardo; Holly Janes; Youyi Fong; Daryl Morris; Daniel E Geraghty; Gustavo H Kijak; Paul T Edlefsen; Nicole Frahm; Brendan B Larsen; Sodsai Tovanabutra; Eric Sanders-Buell; Allan C deCamp; Craig A Magaret; Hasan Ahmed; Jodie P Goodridge; Lennie Chen; Philip Konopa; Snehal Nariya; Julia N Stoddard; Kim Wong; Hong Zhao; Wenjie Deng; Brandon S Maust; Meera Bose; Shana Howell; Adam Bates; Michelle Lazzaro; Annemarie O'Sullivan; Esther Lei; Andrea Bradfield; Grace Ibitamuno; Vatcharain Assawadarachai; Robert J O'Connell; Mark S deSouza; Sorachai Nitayaphan; Supachai Rerks-Ngarm; Merlin L Robb; John Sidney; Alessandro Sette; Susan Zolla-Pazner; David Montefiori; M Juliana McElrath; James I Mullins; Jerome H Kim; Peter B Gilbert; Tomer Hertz
Journal:  J Virol       Date:  2014-05-14       Impact factor: 5.103

2.  TwoPhaseInd: an R package for estimating gene-treatment interactions and discovering predictive markers in randomized clinical trials.

Authors:  Xiaoyu Wang; James Y Dai
Journal:  Bioinformatics       Date:  2016-07-04       Impact factor: 6.937

3.  FCGR2C polymorphisms associate with HIV-1 vaccine protection in RV144 trial.

Authors:  Shuying S Li; Peter B Gilbert; Georgia D Tomaras; Gustavo Kijak; Guido Ferrari; Rasmi Thomas; Chul-Woo Pyo; Susan Zolla-Pazner; David Montefiori; Hua-Xin Liao; Gary Nabel; Abraham Pinter; David T Evans; Raphael Gottardo; James Y Dai; Holly Janes; Daryl Morris; Youyi Fong; Paul T Edlefsen; Fusheng Li; Nicole Frahm; Michael D Alpert; Heather Prentice; Supachai Rerks-Ngarm; Punnee Pitisuttithum; Jaranit Kaewkungwal; Sorachai Nitayaphan; Merlin L Robb; Robert J O'Connell; Barton F Haynes; Nelson L Michael; Jerome H Kim; M Juliana McElrath; Daniel E Geraghty
Journal:  J Clin Invest       Date:  2014-08-08       Impact factor: 14.808

4.  Case-only trees and random forests for exploring genotype-specific treatment effects in randomized clinical trials with dichotomous endpoints.

Authors:  James Y Dai; Michael LeBlanc
Journal:  J R Stat Soc Ser C Appl Stat       Date:  2019-07-08       Impact factor: 1.864

5.  Augmented case-only designs for randomized clinical trials with failure time endpoints.

Authors:  James Y Dai; Xinyi Cindy Zhang; Ching-Yun Wang; Charles Kooperberg
Journal:  Biometrics       Date:  2015-09-08       Impact factor: 2.571

6.  Case-only approach to identifying markers predicting treatment effects on the relative risk scale.

Authors:  James Y Dai; C Jason Liang; Michael LeBlanc; Ross L Prentice; Holly Janes
Journal:  Biometrics       Date:  2017-09-28       Impact factor: 2.571

7.  Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial.

Authors:  Shuying S Li; Peter B Gilbert; Lindsay N Carpp; Chul-Woo Pyo; Holly Janes; Youyi Fong; Xiaoying Shen; Scott D Neidich; Derrick Goodman; Allan deCamp; Kristen W Cohen; Guido Ferrari; Scott M Hammer; Magdalena E Sobieszczyk; Mark J Mulligan; Susan P Buchbinder; Michael C Keefer; Edwin DeJesus; Richard M Novak; Ian Frank; M Juliana McElrath; Georgia D Tomaras; Daniel E Geraghty; Xinxia Peng
Journal:  J Virol       Date:  2019-10-15       Impact factor: 6.549

8.  Leaky vaccines protect highly exposed recipients at a lower rate: implications for vaccine efficacy estimation and sieve analysis.

Authors:  Paul T Edlefsen
Journal:  Comput Math Methods Med       Date:  2014-05-07       Impact factor: 2.238

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.